SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Roger's 1997 Short Picks
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: poodle who wrote (8295)12/13/1997 4:01:00 PM
From: Hank  Read Replies (1) of 9285
 
Poodle,

I believe I can answer your questions about Vasomax. If Ansensio is correct about the poor quality of the clinical trials, and from what I've seen he is, then the FDA will not approve Vasomax based on this fact alone. ZONA will have to conduct much more extensive and more expensive clinical trials to convince the FDA. The question is do they have the money to do so or, if not, where will they get it? I think they can't afford these types of trials because they can run into the hundreds of millions. I also think that since phentolamine is an anti-hypertension drug, the FDA is going to be very hard to convince that Vasomax is safe. People who have normal blood pressure shouldn't be taking drugs like this and people who suffer from hypertension that are already taking other anti-hypertension drugs certainly shouldn't be taking drugs like this. A drop in blood pressure blow the normal range can cause dizzyness and loss of consciouness. As for Schering-Plough, I believe they've offered to market Vasomax should the FDA approve it The 10 million is just Schering-Ploughs way of keep their foot in the door should ZONA be lucky enough to get approval. The competition for licensing drugs from smaller companies like ZONA is fearce, so large drug companies are often willing to spend a few bucks on the long shots in order to increase their chances for securing a winner. However, I would be very surprised to see Schering-Plough come up with the substantial amount of money ZONA will need to get past the FDA. Companies like Schering-Plough may gamble a few million here and there on deals like this but they aren't fools.

Hank
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News